Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on ...
Ophthalmology Times

FDA Clears IND application for GenEditBio’s GEB-101 in TGFBI corneal dystrophy

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...
MyHorryNews

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...
Seeking Alpha

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Study will evaluate drug's potential neuro-restorative mechanism(s) of action for improving synaptic health and cognitive function in MS patients NEW YORK, July 19, 2023 /PRNewswire/ -- Synaptogenix, ...